Peer-reviewed Abstracts

2018   │  2017 │  2016 │  2015  2014  │  2013  │  2012  │  2011  │  2010  │  2009 – 2000  │  1999 – 1992

2017

  • Bergamasco A, Castillon G, Moride Y. Ethical requirements for the conduct of Drug Utiliszation Studies in Latin America: A Cross-Sectional Survey. In: Value Health. 2017; 20(9):A909. doi: http://dx.doi.org/10.1016/j.jval.2017.08.2802. [published online first: October – November 2017].
  • Faure M, Castilloux AM, Moride Y, Lillo-Le-Louet A. Treatment practices for acute ischemic stroke (AIS) in Quebec (Canada), Pharmacoepidemiol Drug Saf. 2017;26(S2):145. doi: 10.1002/pds.4275. [published online first: 22 August 2017].
  • Castillon G, Moride Y, Salvo F. Social impact of adverse drug reactions in the Canada Vigilance Program, Pharmacoepidemiol Drug Saf. 2017;26(S2):642. doi: 10.1002/pds.4275. [published online first: 22 August 2017].
  • Lemieux-Uresandi D, Bergamasco A, Moride Y. Mapping Of Real-World Data Sources For Asthma In Europe, Pharmacoepidemiol Drug Saf. 2017;26(S2):926. doi: 10.1002/pds.4275. [published online first: 22 August 2017].
  • Moride Y, Castillon G, Lemieux-Uresandi D, Béland S.G, Moura C, Faure M, Wells G, Pilote L,Bernartsky S A Systematic Review of Interventions and Programs Targeting Appropriate Prescribing of Opioids. Pharmacoepidemiol Drug Saf. 2017;26(S2):1057. doi: 10.1002/pds.4275. [published online first: 22 August 2017].
Top

2016

  • Bergamasco A, Arredondo-Bisono T, Chalem Y, Stanulovic V, Berdeaux G, Moride Y. A systematic review on the epidemiology of NRAS-MUTANT Melanoma in Europe and Australia. In: Value Health. 2016;19(7):A716. doi: 10.1016/j.jval.2016.09.2115. [published online first: November 2016].
  • Bergamasco A, Yuen CY, Kou TD, Moride Y. Mapping of existing data sources for the conduct of Real-World studies in Progressive Supranuclear Palsy (PSP) in North America, Europe and Japan. In: Value Health. 2016;19(7):A851-2. doi: 10.1016/j.jval.2016.08.473. [published online first: November 2016].
  • Yuen CY, Bergamasco A, Moride Y. Mapping of existing data sources for the conduct of Real-World studies on Lung Cancer in China.  In: Value Health. 2016;19(7):A851. doi: 10.1016/j.jval.2016.08.471. [published online first: November 2016].
  • Bergamasco A, Arredondo-Bisono T, Machnicki G, Obando C, Hernandez-Moran JA, Andryc A, Wu X, Pozzo L, Gutta S, Moride Y. Mapping of existing disease-specific data sources in Latin America for the conduct of Real-World studies, Pharmacoepidemiol Drug Saf. 2016;25(S3):605. doi: 10.1002/pds.4070. [published online first: 24 August 2016].
  • Bergamasco A, Dinet J, Berthon A, Gabriel S, Nayroles G, Moride Y. Prevalence of Gastroenteropancreatic and Lung Neuroendocrine Tumours in the European Union, Ann Oncol 2016; 27 (suppl_6): 424PD. doi: 10.1093/annonc/mdw369.09. [published online first: 11 October 2016].
  • Bergamasco A, Yuen CY, Kou TD, Moride Y. Mapping of existing data sources for the conduct of Real-World studies in Duchenne Muscular Dystrophy (DMD) in North America and Europe, Pharmacoepidemiol Drug Saf. 2016;25(S3):605. DOI: 10.1002/pds.4070. [published online first: 24 August 2016].
  • Yuen CY, Bergamasco A, Arredondo-Bisono T, Moride Y. Mapping of existing disease-specific data sources for the conduct of Pharmacoepidemiologic studies in China, Pharmacoepidemiol Drug Saf. 2016;25(S3):606. DOI: 10.1002/pds.4070. [published online first: 24 August 2016].
  • Faure M, Castilloux AM, Moride Y, Lillo-Le-Louet A. Treatment practices for acute ischemic stroke (AIS) in Quebec (Canada), Pharmacoepidemiol Drug Saf. 2016;25(S3):93. DOI: 10.1002/pds.4070. [published online first: 24 August 2016].
Top

2015

  • Bergamasco A, Yousif A, Tremblay C, Thurin N, Moride Y. Ethical Requirements for the Conduct of Drug Utilisation Studies Involving AD Hoc Data Collection: An International Cross-Sectional Survey. In: Value Health. 2015;18(7):A554. doi: 10.1016/j.jval.2015.09.1784. [published online first: 20 October 2015].
  • Bergamasco A, Thurin N, Salib M, Yousif A, Moride Y. Methodological Gaps in the Assessment of the Utility and Burden of Risk Minimisation Interventions. In: Value Health. 2015;18(7):A552-3. doi: 10.1016/j.jval.2015.09.1777. [published online first: 20 October 2015].
  • Frise S, Bergamasco A, Kozmenko M, Salvo F, Moride Y. Assessment of Burden and Economic Impact of the Vandetanib Restricted Distribution Program in Canada. In: Value Health. 2015;18(7):A484. doi: 10.1016/j.jval.2015.09.1322. [published online first: 20 October 2015].
  • Le Louët H, Delumeau J C, Moride Y, Chen WW, Abdoellah SA, Nguyen HA, Shaikh Abdul Rahman S, Suwankesawong W, Thol S. A Harmonised Scheme to Support Developing Risk Management Guidelines Beyond ICH Countries. Drug Saf 2015;38:980-981. doi: 10.1007/s40264-015-0346-0. [published online first: 15 September 2015].
  • Thurin N, Castilloux A-M, Reich R, Hermann R, Frise S, Moride Y. Assessing the Feasibility and Performance of the HAWK Electronic Medical Records for Drug Safety Surveillance, Drug Saf 2015;38:1033. doi: 10.1007/s40264-015-0346-0. [published online first: 15 September 2015].
  • Frise S, Bergamasco A, Kozmenko M, Salvo F, Moride Y. An Assessment of Utility and Burden Associated with the Vandetanib (CAPRELSA®) Restricted Distribution Program in Canada, Drug Saf 2015;38:945. doi: 10.1007/s40264-015-0346-0. [published online first: 15 September 2015].
  • Castilloux A-M, Jørgensen KT, Coste F, Moride Y. Patterns of Health Care Utilization among Patients Hospitalized for AcuteIschemic Stroke (AIS) in Canada. Pharmacoepidemiol Drug Saf. 2015;24(S1):485. doi: 10.1002/pds.3838. [published online first: 25 September 2015].
  • Castilloux A-M, Jørgensen KT, Coste F, Moride Y. Outcomes and Patterns of Health Care Usage Among Acute Ischemic Stroke Patients in Canada. Pharmacoepidemiol Drug Saf. 2015;24(S1):484-485. doi: 10.1002/pds.3838. [published online first: 25 September 2015].
  • Tremblay C, Yousif A, Bergamasco A, Moride Y. Gaps in Ethical Policies for the Conduct of Drug Utilization Studies to Assess the Effectiveness of Risk Minimization Interventions. Pharmacoepidemiol Drug Saf. 2015;24(S1):145-146. doi: 10.1002/pds.3838. [published online first: 25 September 2015].
  • Yousif A, Bergamasco A,Tremblay C, Castilloux A-M, Dinet J, Nayroles G, Gabriel S, Moride Y, Mitigating the Paucity-of-Data Problem for Target Population Sizing:Exploring a Model-Based Approach for Advanced Gastroenteropancreatic Neuroendocrine Tumors. Pharmacoepidemiol Drug Saf. 2015;24(S1):378-379. doi: 10.1002/pds.3838. [published online first: 25 September 2015].
  • Xu Y, Zhou X, Suehs BT, Hartzema A, Kahn MG, Moride Y, Sauer B, Liu K, Moll K, Pasquale M, Nair V, Bate A. A Comparative Assessment of Observational Medical Outcomes Partnership and Mini-Sentinel Common Data Models and Analytics: Implications for Active Drug Surveillance. Pharmacoepidemiol Drug Saf. 2015;24(S1):195. doi: 10.1002/pds.3838. [published online first: 25 September 2015].
Top

2014

  • Grimaldi-Bensouda L, Abenhaim L, Amzal B, Moride Y. Does confounding in comparative effectiveness assessment always matter for payers’ decisions? Workshop co-presented at the 19th Annual International Meeting of International Society for Pharmacoeconomics and Outcomes Research (ISPOR); Montreal, Canada; 31 May – 4 June 2014.
  • Moride Y, Kozmenko M, Salvo F, Yousif A, Frise S. Effectiveness of Risk Minimisation Measures for Vandetanib in Canada: A Process and Outcome Evaluation. Pharmacoepidemiol Drug Saf. 2014;23(S1):239-240. doi: 10.1002/pds.3701. [published online first: 30 September 2014].
  • Moride Y, Andrews EB, Perez-Guthann S, Soriano-Gabarró M, Suzart-Woischnik K, Vassilev Z, Raine J. Challenges in Risk minimization evaluation: CIOMS Working Group IX consensus and recent field experience. Pharmacoepidemiol Drug Saf. 2014;23(S1):40-1. doi: 10.1002/pds.3701. [published online first: 30 September 2014].
  • Moride Y, Lynd LD, Ducruet H, Li H, Tournier M, Greenield B. Antidepressants and risk of suicide or self-harm in Canadian youth: A study involving common data models in Quebec and British Columbia. Pharmacoepidemiol Drug Saf. 2014;23(S1). doi: 10.1002/pds.3701. [published online first: 30 September 2014].
  • Gridchyna I, Manley Daumont M, Yousif A, Hirji I, Lees M, Salvo F, Moride Y. Evaluation of current data sources in Europe for the conduct of real-world studies on lung and renal cell carcinoma: A systematic literature review. Value in Health. 2014;17(3):A188. doi: 10.1016/j.jval.2014.03.1100.
Top

2012

  • Grimaldi-Bensouda L, Rouillon F, Astruc B, Rossignol M, Benichou J, Falissard B, Limosin F, Beaufils B, VaivaG, Verdoux H, Moride Y, Fabre A, Thibaut F, Abenhaim L. The CGS Study Group. Does long-acting injectable risperidone mae a difference to the real-life treatment of schizophrenia? Results of the French cohort for the generalstudy of schizophrenia (CGS). Pharmacoepidemiol. & Drug Saf. 2012; 31: S243.
  • Gifkins D, McAuliffe M, Matcho A, Porter J, Chavers S, Ryan P, Moride Y, Ponsillo M, King J, Desai A, Cakana A, Esseltine DL. Second malignancies among multiple myeloma patients exposed to bortezomib and othertreatments: An analysis of the US SEER-Medicare linked database. Pharmacoepidemiol. & Drug Saf. 2012; 31:S464.
Top

2011

  • Nkeng L, Ducruet T, Béland SG,Nekka F, Leloier J, Moride Y. Feasibility of conducting data mining for signal detection using a Canadian administrative claims database (RAMQ). Drug Safety 2011; 34; 908.
  • Moride Y, Thiessard F, Bégaud B. Automated signal detection methods may not be applicable to small and mdeium-sized drug safety databases. DrugSafety 2011; 34: 917.
  • Cloutier AM, Greenfield B,Tournier M, Lynd L, Brabant MJ, Lavoie A, Moride Y. Effectiveness of risk communication for the management of suicidal behaviour in youth treated with antidepressants. Pharmacoepidemiol. & Drug Saf. 2011; 20: S204.
  • Craig C,Tannenbaum, Pariente A, Ducruet T, Moride Y. Patterns of antipsychotic use in the community-dwelling demented elderly population: Impact of regulatory warnings. Pharmacoepidemiol.& Drug Saf. 2011; 20: S296.
  • Kurz X, Leufkens B, BlackburnS, Moride Y, Simmons V, de Vries C. Increasing scientific standards, transparency and independence in pharmacoepidemiological research: Is the concept of ENCePP studies a way forward? Pharmacoepidemiol. & Drug Saf. 2011; 20: S150.
  • DuijnhovenR, Straus SM, van Staa T, Moride Y, Grimaldi L, de Bruin M. Assessment of long-term adverse drug reactions, regulatory needs and methodological challenges. Pharmacoepidemiol. &Drug Saf. 2011; 20: S268.
  • Beland SG, Moride Y, Ducruet T, Tannenbaum C, Preville M. A comorbidity score to predict institutionalization performs better than a score to predict death in a comunity-dwelling elderly population. Pharmacoepidemiol. & Drug Saf. 2011; 20: S295.
Top

2010

  • Béland SG, Pariente A, Kergoat MJ, Latour J, Moride Y. In-hospital therapeutic risk management following a fall in the geriatric population: Taking the evidence to the bedside. International Society of Pharmacoepidemiology 2010.
  • MorideY, Pariente A, Fourrier-Réglat A, Ducruet T, Farrington P. The panacea of study designs in pharmacoepidemiology: Which one? Antipsychotics and myocardial infarct in the demented elderly population. International Society of Pharmacoepidemiology 2010.
  • Nkeng L, Cloutier AM, CraigC, Lelorier J, Moride Y. An Environmental Scan of Risk Minimisation Interventions. International Society of Pharmacoepidemiology 2010.
  • Beland SG, Cloutier AM , Craig C, Preville M, Moride Y. Risk of falls in the elderly population using antipsychotics: A systematic review. International Society of Pharmacoepidemiology
  • Marie Tournier, Moride Y., Brian Greenfield, Guillaume Galbaud du Fort, Thierry Ducruet. Non-persistence to antidepressant drug treatment in the Quebec youth. EPA Section Social Psychiatry Psychiatric Epidemiology, Bergen, Norway, June 16-19, 2010.
Top

2009 – 2000

  • Béland SG, Pariente A, Berbiche J, MorideY. Patterns of Psychotropic Drug Use: A Comparative Study in Alzheimer’s disease and community dwelling elderly populations. Pharmacoepidemiol.and DrugSafety 2009; 18: S1-S273
  • Pariente A, Fourrier-Réglat A,Dragomir A, Moride Y. Impact of non-persistence to cholinesterase inhibitor treatments in demented elderly. Pharmacoepidemiol. and Drug Safety 2009; 18: S1-S273
  • Pariente A, Moride Y, Dragomir A & al. Antipsychotic Use and myocardial infarction in demented patients treated with cholinesterase inhibitors. Pharmacoepidemiol.and Drug Safety 2009; 18: S1-S273
  • Pariente A, Abou Chakra CN, Pinet M,Moride Y. Reporting of Case-Series in drug safety: a review of published studies. Pharmacoepidemiol.and Drug Safety 2009; 18: S1-S273
  • Abou Chakra NC, Moride Y,Greenfield B & al. Validation of claims databases for the ascertainment of adverse events: From descriptive to predictive methodologies. Pharmacoepidemiology and Drug Safety 2009; 18: S1-S273
  • Reynolds MW, Moride Y. Understanding the Prescribing Patterns of Lipid-Lowering agents in the United States and Canada. Pharmacoepidemiology and Drug Safety 2009; 18: S1-S273
  • Béland SG, Moride Y, Pariente A& al. Assessment of the economical impact of non-persistence with antidepressant treatments using the administrative claims database of Quebec (Canada). ISPOR.Rio de Janeiro, Brazil – September 12th 2009.
  • Perreault S, Moride Y, Bérard A, Rahme, E. Workshop on the description reliability and validity of data present in the administrative databases of Québec(Canada). ISPOR. Rio de Janeiro,Brazil – September 12th , 2009
  • Pariente A, Moride Y, Dragomir A & al. Antipsychotic use and myocardial infarction in demented patients treated with cholinesterase inhibitors. ISOP conference, October 2008.
  • Pariente A, Moride Y, Dragomir A & al.Cholinesterase inhibitors in demented patients: impact of treatment non-persistence on institutionalization or death. ISOP conference, October 2008.
  • Pariente A, Pinet M, Moore N, Moride Y. Case series in drug safety surveillance: Are they useful as a risk management tool? ISOP conference, October 2008
  • Wathion N, Blackburn S, Kurz X, Persson I, Moride Y, Sturkenboom M. A European Network of Centres for Pharmacovigilance and Pharmacoepidemiology (ENCePP). Pharmacoepidemiol. & Drug Safety 2008; 17: S26.
  • Pinet M, Pariente A, Méliere Y, MorideY, Moore N. Factors associated with persistence toanti-Alzheimer drugs in France. Pharmacoepidemiol. & Drug Safety 2008; 17: S34.
  • Pariente A, Lebeau M, Tounier M, & al. Pharmacoeconomical comparison across antidepressant treatments: Impact of non-persistence. Pharmacoepidemiol. &Drug Safety 2008; 17: S93.
  • Rossignol M, Abouelfath A, LassalleR & al. The burden of non-steroidalanti-inflammatory drug utilization for musculoskeletal disorders in blue-collarworkers: A population cohort study. Pharmacoepidemiol. & Drug Safety2008; 17: S
  • Moride Y. How to weigh risks and benefits of drugs: Challenges and Methodologies. IXth ClinicalPharmacology & Therapeutics World Congress. Quebec City July 2008
  • , Savoie M, Manika A & al. Disease management program to optimize the use of antidepressants: Results from a pilot study. IXth Clinical Pharmacology & Therapeutics World Congress. Quebec City July 2008
  • Lebeau M, Pariente A, Tournier M, & al. Economical impact of non-persistence to antidepressant treatments:Comparison across products. IXth Clinical Pharmacology &Therapeutics World Congress. Quebec CityJuly 2008
  • Blazejewski S, Blin P, Lignot S& al. Initial treatment effectiveness of acute sinusitis in a representative national cohort. IXthClinical Pharmacology & Therapeutics World Congress. Quebec City July 2008
  • Moride Y, Del Pan G, Raine J, Kawahar A & al. Improvement of the drug regulatory process: International Initiatives. Pharmacoepidemiol. & Drug Safety 2007; 16: S77.
  • Moride Y, Rahme E, Mamdani M and GRASP study group. The Impact of Rofecoxib Withdrawal in Canada and US: What Happened to Chronic Users of Cox-2 Selective Inhibitor (Coxib)? Pharmacoepidemiol. & Drug Safety 2007; 16: S79.
  • Tournier M, Moride Y, Ducruet T & al. Non-Persistence with Antidepressant Therapy in the Quebec Youth. Pharmacoepidemiol. & Drug Safety 2007; 16: S155.
  • Mikaeloff Y, Moride Y, & al. Infant and Toddler Disease Score for risk of hospitalization based on data from administrative claims is useful for pharmacoepidemiologic studies. Pharmacoepidemiol. & Drug Safety 2007; 16: S116.
  • Blouin J, Dragomir A, Moride Y, & al. Impact of non-adherence to bisphosphonates on the incidence of osteoporotic fractures: A nested case-control study. Pharmacoepidemiol.& Drug Safety 2007; 16: S44.
  • Blin P & al. Management of acute sinusitis: result of a French cohort study. Pharmacoepidemiol. & Drug Safety 2007; 16: S172.
  • Blin P & al. Initial treatment effectiveness of acute sinusitis in a representative national cohort. Pharmacoepidemiol.& Drug Safety 2007; 16: S238.
  • Blin P, Blazejewski S, Lignot S. & al. Prise en charge de la sinusite aigue en France et évaluation de l’efficacité du traitement initial en situation réelle. Congrès RICAI (réunion interdisciplinaire de chimiothérapie anti-infectieuse)
  • Moride Y, Lynd L, Abenhaim L, & al. Methods of therapeutic benefit-risk assessment. Pharmacoepidemiol. & Drug Safety 2006; 15: S1.
  • Moride Y, Tournier M, Ducruet T, & al. The impact of visual impairment on the risk of depression and mortality in the Quebec community-dwelling elderly population. Pharmacoepidemiol. & Drug Safety 2006; 15: S53
  • Moride Y, Tournier M, Ducruet T & al. The depletion of susceptibles effect in the assessment of burden-of-illness for pharmacoeconomic studies. Third Canadian Therapeutics Congress, Joint Scientific Meeting, “Therapeutics evolving: bringing the science of innovative treatments into our everyday world”, Toronto, 10-13 May 2006
  • Tournier M, Moride Y, Galbaud du Fort G & al. Sub-optimal duration of antidepressant use in the Quebec elderly population: Comparison across newer products and economical impact. 13th AEP Symposium, AEP Section Epidemiology and Social Psychiatry, Bordeaux, 14-17 June 2006.
  • Jove J, Benichou J, Depont F and the CADEUS Study Team. Factors associated with COX-2 usage patterns: A multinomial analysis in the CADEUS Study. Pharmacoepidemiol. & Drug Safety 2006; 15: S57.
  • Abouelfath A, Droz C, Moore N and The CADEUS Study Team. Methodological implications of the heterogeneity of NSAID users. Pharmacoepidemiol. & Drug Safety 2006; 15: S88.
  • Lassalle R, Benichou J, Depont F, and the CADEUS Study Team. Factors associated with gastroprotective agent usage pattern in NSAID users: A multinomial analysis in the CADEUS Study. Pharmacoepidemiol. & Drug Safety 2006; 15: S241.
  • Droz C, Moore N, Depont F and the CADEUS Study Team. Who were the new COX-2 users in CADEUS? Pharmacoepidemiol. & Drug Safety 2006; 15: S244.
  • Depont F, Moore N, Droz C and the CADEUS Study Team. Prescriber non-participation in the CADEUS Study did not induce patient selection bias. Pharmacoepidemiol. & Drug Safety 2006; 15: S282.
  • Guay MP, Dragomir A, Moride Y, Perreault S. The WHI Publication: What are the changes in pattern of HRT use and the persistence rate? Pharmacoepidemiol. & Drug Safety 2005 ; 14 :S31.
  • Moore N, Blin P, Fourrier-Réglat, Depont F, Droz C, Amouretti M, Benichou J, Moride Y. et al. A description of COX-2 inhibitors and non-selective NSAID users in France, the CADEUS Study. Pharmacoepidemiol. & Drug Safety 2005 ; 14 : S191.
  • Martin K, Moride Y, Latry P, Abouelfath A, Bégaud B. Assessment of Public Health impact of Statin prescription for primary prevention of Myocardial Infarction mortality in real life setting in France? Congrès de la Société Française de Pharmacologie, 26-28 Avril 2005.
  • Martin K, Moride Y, Latry P, AbouelfathA, Bégaud B. Assessment of Public Health impact of Statin prescription for secondary prevention of Myocardial Infarction mortality in real life setting in France? Congrès de la Société Française de Pharmacologie, 26-28 Avril 2005.
  • Pilette D, Moride Y, Weinstock D, Perreault S, Lachaine J, Kennedy W, Lesk M. The impact of informed consent for administrative database linkage on the validity of pharmacoepidemiological studies. (CAPT, 2005)
  • Moride Y, Galbaud du Fort G, Ducruet T, Perreault S, Boivin JF. Economical impact of non-adherence to antidepressant treatment in the Quebec elderly population (CAPT, 2005)
  • Moride Y, Ducruet T, Perreault S, Galbaud du Fort G, Boivin JF. Comparison of cost-effectiveness ratio across individual antidepressants in the elderly outpatient population (CAPT, 2005).
  • Ferrarotto F, Moride Y, Bégaud B. Signaling Possible Gender Effect in a spontaneous reporting system: Cardiac Effects associated with the Use of Antibiotics (CAPT, 2005)
  • Moride Y, Schneeweiss S, Moore N, Heerdink ER, Boivin JF, Bénichou J. Methodological workshop on sampling strategies applied to drug utilization studies. Pharmacoepidemiol. & Drug Safety 2004; 13: S26.
  • Sampalis J, Moride Y. Estimating relative risk of injury associated with exposure to prescription medications: Conflicting results from case-crossover and case-time-control analyses. Pharmacoepidemiol. & Drug Safety 2004; 13: S14.
  • Bissonnette S, Denis E, Moride Y, Sampalis J. Gastrointestinal safety and Vioxx effectiveness in patients at high risk for gastric injury. Pharmacoepidemiol. & Drug Safety 2004; 13: S289.
  • Perreault S, Dragomir AE, Blais L, Moride Y, Rossignol M, Ste-Marie LG, Fernandes J. A population-based study of the effectiveness of antiresorptive agents on risk reduction of fracture. Pharmacoepidemiol. & Drug Safety 2004; 13: S314
  • Moride Y., Ducret T, Lavoie F, Boivin JF, Rochon S. Comparison of the characteristics of patients who are prescribed coxibs and traditional NSAIDs in Quebec (year 2002). 1st Prize Poster Presentation. Can.J.Clin.Pharmacol. 2004.
  • Moride Y., Ducruet T., Rochon S., Lavoie F. Patterns of use of Cox-2 inhibitors and non-selective NSAIDs in the elderly outpatient population of Quebec. ISPOR conference, Barcelona Nov. 11, 2003
  • Moride Y. , Ducruet T, Rochon S, Lavoie F. Adherence to the Canadian consensus guidelines for the prescription of NSAIDs. Can.J.Clin.Pharmacol. 2003; 10: 24.
  • Moride Y., Ducruet T, Rochon S, Lavoie F. Persistency and patterns of use of Cox-2 inhibitors and non-selective NSAID. Can.J.Clin.Pharmacol. 2003; 10: 44.
  • Moride Y., Ducruet T, Reynolds M, Zhao S. Non-steroidal anti-inflammatory drug use: Impact of risk factors for gastropathy on prescribing practices. Pharmacoepidemiol. & Drug Safety 2002; 11 (suppl.1): S128.
  • Lagnaoui R, Moride Y, Wolfson C, Ducruet T, Bégaud B, Moore N. The risk of cognitive impairment in elderly community-dwelling women after benzodiazepine use. Pharmacoepidemiol. & Drug Safety 2002; 11 (suppl.1): S80.
  • Rossignol M, Moride Y, Perreault S, Boivin JF, Ste-Marie LG, Robitaille Y, Poulin de Courval L, Fautrel. Recommendations for the prevention of osteoporosis and fragility fractures: Internation comparison and synthesis. ISTAHC, 2002.
  • Perreault S, Desgagné A, Boucher JM, Blais L, Moride Y, Rossignol M, LeLorier J, Ste.Marie LG. Trends and determinants of antiresorptive therapies use among women with previous osteoporotic fracture. Pharmacoepidemiol. & Drug Safety 2002; 11 (suppl.1): S204.
  • Martel MC, Moride Y, Gauthier L, Cadrin C, Grégoire JP. A comprehensive database on the use of medications and medical services during pregnancy among women with pre-existing chronic conditions: a pilot study. Pharmacoepidemiology & Drug Safety 2001; 9:
  • Martel MC, Moride Y, Gauthier L, Cadrin C, Bussières JF. Development of a research tool to measure the use of medications and medical services during pregnancy. OTIS Conference, Montreal June 2001.
  • Perreault S, Levinton C, Moride Y, Ste-Marie LG, Laurier C, Crott R, Bellavance F. Validation of a decision model for pharmacological primary prevention in post-menopausal women. Pharmacoepidemiology & Drug Safety 2001; 9: S190.
  • Perreault S, Levinton C, Moride Y, Ste-Marie LG, Laurier C, Crott R, Bellavance F. Menopausal status : Validation of a Markov model for women-specific decisions about drug therapy. Can. J. Clin. Pharmacol. 2001; 8: 28.
  • Perreault S, Moride Y, Ste-Marie LG, Laurier C. Ménopause: Validation d’un modèle de décision de traitements pharmacologiques. Sci.2001; 1(suppl.).
  • Perreault S, Levinton C, Moride Y, Ste-Marie LG, Laurier C, Bellavance F, Crott R. Validation of decision model for pharmacological primary prevention in post-menopausal women. Réseau FRSQ sur l’’tilisation des Médicaments, Mai 2001.
  • Moride Y., Galbaud du Fort G, Monette J, Ducruet T. et al. Predictors of adherence to antidepressant treatment in a population of elderly outpatients. Pharmacoepidemiol. & Drug Safety 2000; 9(suppl.1): S68
  • Moride Y., Laurier C, Kennedy W et al. Database linkage – The impact of informed consent on study validity. Pharmacoepidemiol. & Drug Safety 2000; 9 (suppl.1): S129
  • Ducruet T, Moride Y., Galbaud du Fort, Laurier C. et al. The impact of information guides on the prescription of antidepressants in the elderly population.. Pharmacoepidemiol. & Drug Safety 2000; 9(suppl.1): S122
  • Moride Y., Galbaud du Fort G, Ducruet T, Monette J. Predictors of adherence to antidepressant treatment in the Quebec elderly population. Can. J. Clin. Pharmacol. 2000; 7: 66.
  • Laurier C, Moride Y., Kennedy W. Increase in reported use of medication in Quebec: an analysis of ante Québec 1987 and 1992-1993 data. Can. J. Clin. Pharmacol. 2000; 7: 63.
Top

1999 – 1992

  • Moride Y., Galbaud du Fort G., Boivin JF., Cole M., Vida S., McCusker J., LeLorier J., Monette J. Drugs as a risk factor for delirium in the elderly. Post-marketing Surveillance 1999; 8 (suppl.2): S126. (1st prize poster presentation).
  • Ducruet T., Moride Y., Galbaud du Fort G., Monette J., Boivin JF, Champoux N. Patterns of antidepressant utilization in Quebec (1992-1996). Colloque du Réseau FRSQ sur l’Utilisation des Médicaments, Sherbrooke, 1999.
  • Moride Y., Wolfson C., Perrault A., Vida S., Bell L. Health services utilization by Alzheimer’s disease patients. Post-marketing Surveillance 1997; 6(suppl.2): S113.
  • Wolfson C., Moride Y., Perrault A., Vida S. Tacrine as a treatment for Alzheimer’s disease: a best evidence synthesis. Neuroepidemiology 1997; 16: 257.
  • Egan M., Wolfson C., Moride Y., Monette J., Hanley J. Les usages suboptimaux des benzodiazepines: Les facteurs reliés aux patients peuvent-ils expliquer la variation parmi lesprescripteurs?’ publié dans the proceedings of le 13ieme congrès scientifique annuel de la Société québécoise de gériatrie (Montréal – le 29 et 30 mai, 1997).
  • Perrault A., Poissan A., Wolfson C., Moride Y., Vida S. Appréciation critique des échelles de mesures cognitives utilisées dans les essais cliniques de la Tacrine pour le traitement de la maladie d’Alzheimer. L’Année Gérontologique
  • Moride Y., Herings R., Edlavitch S., Lalonde L. The Internet as a tool for pharmacoepidemiology. Pharmacoepidemiology and Drug Safety 1996; 5(suppl.1): S115
  • Miremont G., Haramburu F., Moride Y., Gomez MP. et al. Prescriptions de traitements hormonaux chez la femme enceinte: données d’une étude de cohorte. 17ièmes Journées Françaises de Pharmacovigilance, Paris 9-10 nov. 1995.
  • Moride Y., Wolfson C., Perrault A., Sherwin B. Estrogen replacement therapy and cognitive impairment in elderly women: a pilot case-control study.Pharmacoepidemiology and Drug Safety 1995; 4 suppl.1: S87.
  • Wolfson C., Moride Y., Perrault A., Abenhaim L., Esdaile J. A case-control analysis of NSAIDs and Alzheimer’s Disease. Pharmacoepidemiology and Drug Safety 1995; 4 suppl.1: S87.
  • Haramburu F., Miremont G., Moride Y. et al. Drug prescription during pregnancy: a cohort study. Pharmacoepidemiology and Drug Safety 1995; 4 suppl.1: S74
  • Melnychuk D., Monette J.,Moride Y., Abenhaim L. The epidemiology of anti-ulcer therapy in the Quebec elderly. Pharmacoepidemiology and Drug Safety 1995; 4 suppl.1: S88.
  • Bégaud B., Haramburu F., Moride Y. et al. The fallacy of using the normal distribution in pharmacoepidemiology. Pharmacoepidemiology and Drug Safety 1995; 4 suppl.1: S66
  • Schaeverbeke T., Hallé O., Moride Y., Constans J. et al. Systemic sclerosis and prolonged exposure to toxics. Arthritis Rheum., 1995, vol.38, no.9 (suppl.): S332.
  • Abenhaim L., Moride Y., Bégaud B. et al. International case-control studies in pharmacoepidemiology: opportunities and methodological issues. Pharmacoepidemiology and Drug Safety 1994; 3 suppl.1: S73.
  • Moride Y., Haramburu F., Bégaud B. Assessment of underreporting of adverse events in pharmacovigilance. Pharmacoepidemiology and Drug Safety 1994; 3 suppl.1: S73.
  • Abenhaim L., Moride Y. The effect of baseline susceptibility on the relative gastro-toxicity of individual NSAIDs in the elderly: a study with the Quebec database. Post-marketing Surveillance 1993; 7: 176.
  • Bégaud B., Abenhaim L., Tubert-Bitter P., Moride Y., Faich G. Post-marketing cohort studies: are they worth the trouble? Post-marketing Surveillance 1993; 7: 181.
  • Moride Y., Abenhaim L., Esdaile J. Risk of upper gastrointestinal bleeding: enteric-coated aspirin versus non-aspirin NSAIDs. Post-marketing Surveillance 1992
  • van Staa T., Abenhaim L., Moride Y. Utilization dynamics, time-windows and risk comparisons in record linkage studies. Post-marketing Surveillance 1992
  • Abenhaim L., Leufkens H. Moride Y., Herings R. et al. Workshop on the methodological aspects of exposure characterization in pharmacoepidemiology. Post-marketing Surveillance 1992; 6: 1.